Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study-Reference-Cited by-同舟云学术

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

Published:2018-03 Issue:2 Volume:12 Page:126-132
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Wei Lai,Xie Qing,Hou Jin Lin,Tang Hong,Ning Qin,Cheng Jun,Nan Yuemin,Zhang Lunli,Li Jun,Jiang Jianning,McNabb Brian,Zhang Fangqiu,Camus Gregory,Mo Hongmei,Osinusi Anu,Brainard Diana M.,Gong Guozhong,Mou Zhuangbo,Wu Shanming,Wang Guiqiang,Hu Peng,Gao Yanhang,Jia Jidong,Duan Zhongping

Funder

Gilead Sciences

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/article/10.1007/s12072-018-9856-z/fulltext.html

Reference27 articles.

1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.

2. Rao HY, Li H, Chen H, Shang J, Xie Q, Gao Z-L, Li J, et al. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study. J Gastroenterol Hepatol. 2017;32:244–252.

3. PEGASYS®, Roche Pharmaceuticals. PEGASYS® (peginterferon alfa-2a) Injection for Subcutaneous Use. U.S. Prescribing Information. Nutley; 2015 (Revised March)

4. Omata M, Kanda T, Wei L, Yu M-L, Chuang W-L, Ibrahim A, Lesmana CRA, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hep Intl. 2016;10:702–726.

5. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China;Infectious Diseases and Therapy;2023-10-19

2. Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China;2023-05-05

3. Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein;Drug Research;2022-06-20

4. Efficacy and safety of direct‐acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: A multicenter, real‐world study in Guangdong, China;Journal of Medical Virology;2022-05-31

5. Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study;Journal of Viral Hepatitis;2022-04-08